Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial


This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/7324/

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:
Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

http://sro.sussex.ac.uk
Use of probiotic *Lactobacillus* preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial

Mary Hickson, research dietitian,¹ Aloysius L D’Souza, research fellow,² Nirmala Muthu, research nurse,³ Thomas R Rogers, professor of clinical microbiology and honorary consultant (Hammersmith Hospitals NHS Trust),⁴ Susan Want, clinical scientist,⁵ Chakravarthi Rajkumar, senior lecturer,² Christopher J Bulpitt, professor of geriatric medicine⁵

**ABSTRACT**

**Objective** To determine the efficacy of a probiotic drink containing *Lactobacillus* for the prevention of any diarrhoea associated with antibiotic use and that caused by *Clostridium difficile*.

**Design** Randomised double blind placebo controlled study.

**Participants** 135 hospital patients (mean age 74) taking antibiotics. Exclusions included diarrhoea on admission, bowel pathology that could result in diarrhoea, antibiotic use in the previous four weeks, severe illness, immunosuppression, bowel surgery, artificial heart valves, and history of rheumatic heart disease or infective endocarditis.

**Intervention** Consumption of a 100 g (97 ml) drink containing *Lactobacillus casei*, *L bulgaricus*, and *Streptococcus thermophilus* twice a day during a course of antibiotics and for one week after the course finished. The placebo group received a longlife sterile milkshake.

**Main outcome measures** Primary outcome: occurrence of *C difficile* toxin and diarrhoea. Secondary outcome: presence of *C difficile* toxin and diarrhoea.

**Results** 7/57 (12%) of the probiotic group developed diarrhoea associated with antibiotic use compared with 19/56 (34%) in the placebo group (P=0.007). Logistic regression to control for other factors gave an odds ratio 0.25 (95% confidence interval 0.07 to 0.85) for use of the probiotic, with low albumin and sodium also increasing the risk of diarrhoea. The absolute risk reduction was 21.6% (6.6% to 36.6%), and the number needed to treat was 5 (3 to 15). No one in the probiotic group and 9/53 (17%) in the placebo group had diarrhoea caused by *C difficile* (P=0.001). The absolute risk reduction was 17% (7% to 27%), and the number needed to treat was 6 (4 to 14).

**Conclusion** Consumption of a probiotic drink containing *L casei*, *L bulgaricus*, and *S thermophilus* can reduce the incidence of antibiotic associated diarrhoea and *C difficile* associated diarrhoea. This has the potential to decrease morbidity, healthcare costs, and mortality if used routinely in patients aged over 50.

**Trial registration** National Research Register N0016106821.

---

**INTRODUCTION**

There is increasing evidence that probiotics are beneficial in a range of gastrointestinal conditions, including infectious diarrhoea and that related to antibiotic use.¹ Probiotics are defined as “live micro-organisms which when administered in adequate amounts confer a health benefit on the host”² and include *Streptococcus thermophilus*, *Enterococcus* species, *Saccharomyces* species, and various species of lactobacilli and bifidobacteria.

Diarrhoea associated with antibiotic use and caused by *Clostridium difficile* is a complication of treatment with antimicrobial agents and occurs in about 5-25% of patients.³ *C difficile* is responsible for around 15-25% of all cases of diarrhoea associated with antibiotic use, most occurring in older patients, usually in the two to three weeks after cessation of antibiotic treatment.⁴ Lactobacilli, bifidobacteria, and *Streptococcus* species have all been evaluated for the prevention or treatment of diarrhoea associated with antibiotic use and found to be safe.⁵ Several reviews support benefit but still call for large placebo controlled trials to determine species and dose effectiveness for prevention, to show effectiveness in preventing diarrhoea caused by *C difficile*, and to establish effect on length of hospital stay and cost effectiveness.⁶⁷

We undertook a randomised double blind, placebo controlled trial of a commercially available probiotic preparation in older patients in hospital who were receiving antibiotics.

**METHODS**

The hypothesis was that a probiotic *Lactobacillus* preparation would reduce the incidence of antibiotic associated diarrhoea and *C difficile* associated diarrhoea. Our primary outcome was the occurrence of diarrhoea, which was recorded by the nursing staff and authenticated by the researchers. Diarrhoea was defined as more than two liquid stools a day for three or more days in quantities in excess of normal for each patient. The secondary outcome was the occurrence of *C difficile* infection, defined as an episode of diarrhoea combined with the detection of toxins A or B, or both,
from a stool sample (enzyme immunoassay kit, Meridian Bioscience, OH, USA).

Participants
We recruited patients from three London hospitals: Hammersmith, Charing Cross, and Hillingdon. Patients were recruited mainly from orthopaedic, medical, and care of the elderly wards, and included inpatients aged over 50 who were prescribed antibiotics (single or multiple antibiotics, oral or intravenous) and were able to take food and drink orally. Initially patients had to be able to give written informed consent, though half way through the trial we received ethical approval to recruit patients with cognitive impairment. Nevertheless, only seven patients had an abbreviated mental test score\(^9\) less than 7 (four in the control group and three in the probiotic group).

Our exclusion criteria were diarrhoea on admission or within the preceding week, reported recurrent diarrhoea, or bowel pathology that could result in diarrhoea; intake of high risk antibiotics (clindamycin, cephalosporins, aminopenicillins) or more than two courses of other antibiotics in the past four weeks to exclude pre-existing diarrhoea associated with antibiotic use; severe life threatening illness, immunosuppression, bowel surgery, artificial heart valve, history of rheumatic heart disease, or history of infective endocarditis\(^5\); regular probiotic treatment before admission; and lactose intolerance or intolerance to dairy products.

Interventions
The treatment group received a probiotic yoghurt drink (Actimel, Danone, France) containing \(L\) casei \(\text{DN-114 001 (} L\text{ casei imunitass}\) \(1.0 \times \text{10}^8\) colony forming units/ml), \(S\) thermophilus \((1.0 \times \text{10}^8\) cfu/ml), and \(L\) bulgaricus \((1.0 \times \text{10}^7\) cfu/ml). The placebo group received a longlife, sterile milkshake (Yazoo, Campina, Netherlands). We carried out general lactobacillus counts on a sample of the probiotic drinks to ensure they were active. \(L\) casei imunitass has been shown to travel through the human gut and survive into the large intestine,\(^10\) thus meeting one criterion of a probiotic. Participants began using the drinks within 48 hours of starting antibiotic therapy and continued doing so for one week after they stopped taking antibiotics. They drank 100 g (97 ml) twice daily half an hour before or one to two hours after meals. Researchers verified participants’ consumption and recorded missed or refused drinks to assess compliance.

Study plan
The admitting medical team identified potential patients who had been prescribed antibiotics and the researchers approached them within 48 hours of the first antibiotic dose. Once they obtained informed consent, they collected baseline data and prescribed the randomised study drink. The hospital pharmacy dispensed the drink. A baseline stool sample was collected to screen for asymptomatic \(C\) difficile carriage. Bowel movements were monitored with stool charts, which were checked every weekday for accuracy. When there was evidence of diarrhoea a stool sample was analysed for \(C\) difficile toxin.

Once the antibiotic course was finished a final week of study drink was dispensed and a final follow-up date fixed for four weeks later. Patients who were discharged taking antibiotics were provided with enough drink on discharge to cover the period they had to take antibiotics plus one week. Researchers followed up participants for four weeks from discharge with weekly phone calls to ask about diarrhoea and compliance. If participants had diarrhoea, the researchers collected a further stool sample to check for \(C\) difficile toxin.

Sample size
With \(\alpha=0.05\) and a power of 90% to detect an absolute difference of 20% between the proportion of patients with antibiotic associated diarrhoea in the placebo (assumed at 30%) and probiotic (assumed at 10%) groups we estimated that we needed a sample size of 164 (82 in each group).

Randomisation
An independent statistician generated the random allocation sequence, which was stratified for hospital, sex, and two age groups (50-69 and \(\geq 70\)). The sequence was given to the pharmacy on each site.

Blinding
Actimel is sold in 100 g white plastic bottles with removable labels; Yazoo is packaged similarly but in 200 ml bottles. We chose Yazoo as placebo because it looks identical in colour and consistency to Actimel but is an ultra high temperature treated product and has no
bacterial content. The pharmacies removed the commercial labels, then applied study labels to identify the patient, the drink’s “use by” date, and storage instructions. We could not find a placebo in an identical bottle to Actimel.

Patients and researchers were blind to the study drink as they did not see the bottle the drink came in. Nursing staff dispensed the drinks and were instructed to pour 100 ml into a cup for the patient; they were not told which bottle contained which drink. Older people in the UK are not generally familiar with these products, but it is possible some patients might have recognised the taste. However, we had excluded people who regularly took this or other probiotic products from the study.

Potential bias through unblinding was possible but unlikely, and the outcome measure was checked and agreed between two or more people. Microbiology staff who were blind to the study grouping assessed occurrence of \textit{C} \textit{difficile} by analysis of a stool sample from patients who had diarrhoea.

**Statistical methods**

We used Fisher’s exact test to compare rates of antibiotic associated diarrhoea and \textit{C} \textit{difficile} associated diarrhoea and logistic regression (block entry with removal of non-significant variables) to establish which factors influenced the occurrence of diarrhoea and to estimate the adjusted odds ratio for treatment effect.

**RESULTS**

From November 2002 to January 2005, 135 patients entered the study (figure). The most common reason for exclusion (61% of patients) was the likelihood of diarrhoea from causes unrelated to antibiotics. A further 21% of patients were excluded because of possible safety concerns, and 18% were not able to give informed consent nor were relatives willing or available to give assent. Only one patient was excluded because of a dairy allergy.

There were no reported adverse events related to the study drinks. In the 24 samples we tested for lactobacillus the mean count was $2.2 \times 10^8$ cfu/ml (range $0.35 \times 10^8-4.6 \times 10^8$). We found no bacterial content in the Yazoo samples.

There were no clinically important differences between the two groups at baseline (table 1). Most patients received one antibiotic, but about 40% received two (table 1). The most common reasons for antibiotic use were respiratory infection (49%) or prophylaxis before or after surgery (25%) (usually orthopaedic). Compliance was assessed by the percentage of prescribed drinks that were consumed: 75% (interquartile range 55-91%) of the probiotic and 79% (63-94%) of the control drink. The main reason for compliance rates falling below 100% were delivery and distribution failures, rather than palatability. One patient in each group was positive for \textit{C} \textit{difficile} toxin at baseline but had no diarrhoea; neither patient subsequently developed diarrhoea.

The primary analysis was intention to treat and included all patients with available end point data (table 2). We could not complete follow-up on 16% (22/135; 12 in probiotic group, 10 in placebo group) as we were unable to contact them at home despite numerous phone calls and written communications (16) or they had withdrawn (6) from the study, thus the analysis for occurrence of antibiotic associated diarrhoea included 113 patients (56 in control and 57 in probiotic group). Four patients were not tested for \textit{C} \textit{difficile} (one in probiotic group, three in control group) and thus were not included in the analysis for occurrence of diarrhoea associated with \textit{C} \textit{difficile}. We found a significant reduction in both the incidence of antibiotic associated diarrhoea and \textit{C} \textit{difficile} associated diarrhoea (P=0.007) and \textit{C} \textit{difficile} associated diarrhoea (P=0.001) in the probiotic group.


Table 1 Baseline characteristics of study participants. Figures are numbers (percentages) of patients unless stated otherwise

<table>
<thead>
<tr>
<th></th>
<th>Probiotic (n=69)</th>
<th>Control (n=66)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women</td>
<td>39 (57)</td>
<td>34 (52)</td>
</tr>
<tr>
<td>White European</td>
<td>61 (88)</td>
<td>59 (89)</td>
</tr>
<tr>
<td>Mean (SD) age (years)</td>
<td>73.7 (11.1)</td>
<td>73.9 (10.5)</td>
</tr>
<tr>
<td>Median (IQR) BMI</td>
<td>25.5 (20.6-31.5)</td>
<td>23.7 (19.7-30.5)</td>
</tr>
<tr>
<td>Median (IQR) white cell count (/l)</td>
<td>32.3 (32.7-36.1)</td>
<td>32.7 (6.1)</td>
</tr>
<tr>
<td>Median (IQR) plasma sodium (mmol/l)</td>
<td>9.0 (6.8-13.3)</td>
<td>9.5 (7.0-13.1)</td>
</tr>
<tr>
<td>Median (IQR) C reactive protein (mg/l)</td>
<td>138.0 (135-140)</td>
<td>137.0 (135-139)</td>
</tr>
<tr>
<td>Median (IQR) thyroid stimulating hormone (mU/l)</td>
<td>37.0 (13.0-118.0)</td>
<td>46.0 (15.8-140.0)</td>
</tr>
<tr>
<td>Median (IQR) thyroxine (pmol/l)</td>
<td>1.17 (0.56-2.09)</td>
<td>0.9 (0.6-1.74)</td>
</tr>
<tr>
<td>Median (IQR) length of stay (days):</td>
<td>15.5 (14.0-17.2)</td>
<td>15.3 (13.0-16.7)</td>
</tr>
<tr>
<td>Before randomisation</td>
<td>1.0 (1.0-2.0)</td>
<td>1.0 (1.0-2.0)</td>
</tr>
<tr>
<td>After randomisation</td>
<td>9.0 (5.0-16.0)</td>
<td>8.0 (4.5-14.0)</td>
</tr>
<tr>
<td>Alcohol drinkers</td>
<td>34 (69)</td>
<td>33 (50)</td>
</tr>
<tr>
<td>Median (IQR) alcohol units/week in drinkers</td>
<td>6 (2-12)</td>
<td>9 (3-21)</td>
</tr>
<tr>
<td>Smokers</td>
<td>19 (28)</td>
<td>11 (17)</td>
</tr>
<tr>
<td>Mean (SD) No of cigarettes/week in smokers</td>
<td>82 (66)</td>
<td>102 (87)</td>
</tr>
<tr>
<td>No of antibiotics prescribed:</td>
<td>40 (58)</td>
<td>34 (52)</td>
</tr>
<tr>
<td>2</td>
<td>26 (38)</td>
<td>29 (64)</td>
</tr>
<tr>
<td>3</td>
<td>3 (4)</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Risk of antibiotic causing diarrhoea*:</td>
<td>0 (0)</td>
<td>1 (1.5)</td>
</tr>
<tr>
<td>Low</td>
<td>26 (38)</td>
<td>19 (29)</td>
</tr>
<tr>
<td>High</td>
<td>43 (62)</td>
<td>46 (70)</td>
</tr>
</tbody>
</table>

**Indication for antibiotics:**

<table>
<thead>
<tr>
<th></th>
<th>Probiotic (n=69)</th>
<th>Control (n=66)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory tract infection</td>
<td>33 (48)</td>
<td>33 (50)</td>
</tr>
<tr>
<td>Prophylaxis before/after surgery</td>
<td>17 (25)</td>
<td>17 (26)</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>10 (15)</td>
<td>10 (15)</td>
</tr>
<tr>
<td>Other†</td>
<td>7 (10)</td>
<td>8 (10)</td>
</tr>
<tr>
<td>Missing</td>
<td>2 (3)</td>
<td>1 (2)</td>
</tr>
</tbody>
</table>

*Low risk=tetracyclines (doxycycline), sulphonamides (trimethoprim), macrolides (azithromycin, clarithromycin, erythromycin), quinolones (ciprofloxacin); high risk=aminopenicillin (amoxicillin, benzylpenicillin, co-amoxiclav, flucloxacillin), cephalosporins (cefalexin, cefazidime, cefuroxime).†

†Interquartile range; BMI=body mass index.

†IQR=interquartile range; BMI=body mass index.
Table 2 | Total number of cases of antibiotic associated diarrhoea (including cases positive for C difficile) and proportion who were positive or negative for C difficile toxin (all patients followed up in hospital and after discharge)

<table>
<thead>
<tr>
<th>Diarrhoea</th>
<th>Probiotic</th>
<th>Control</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yes</td>
<td>7 (12)</td>
<td>19 (34)</td>
<td>0.007</td>
</tr>
<tr>
<td>No</td>
<td>50 (88)</td>
<td>37 (66)</td>
<td></td>
</tr>
<tr>
<td>No of patients</td>
<td>57†</td>
<td>56†</td>
<td></td>
</tr>
<tr>
<td>C difficile toxin</td>
<td>Positive</td>
<td>0</td>
<td>9 (17)</td>
</tr>
<tr>
<td>No</td>
<td>56 (100)</td>
<td>44 (83)</td>
<td></td>
</tr>
<tr>
<td>No of patients</td>
<td>56‡</td>
<td>53‡</td>
<td></td>
</tr>
</tbody>
</table>

*Fisher’s exact test. †22/135 patients lost to follow-up or withdrew. ‡4/113 patients not tested for C difficile.

A probiotic freely available in the UK. Additionally, we were able to show the bacterial content of the product, included a four week absence of antibiotic use before enrolment, and tested for C difficile toxin in all patients with diarrhoea.

In vitro studies have shown that different bacterial strains work differently, and previous trials have produced conflicting results; thus other strains may not produce the same beneficial effect as the strains tested here. We could not establish which bacteria species are effective from the three strains in this probiotic drink; the three species may be working synergistically to prevent diarrhoea or alternatively one species may be more effective than another. Therefore, our results cannot be extrapolated to other probiotic products, which must be tested in similar trials.

An obvious methodological weakness is the possibility of unblinding of the researchers and patients. We did, however, take precautions to avoid unblinding and, most importantly, several people confirmed the presence of diarrhoea. The loss to follow-up of 16% of the study population is also a weakness, though the numbers lost in each group were similar (12 in the probiotic group and 10 in the control group) and should not significantly alter the results.

The figure illustrates the difficulties in recruitment for this study; of 1760 patients screened only 135 took part. This raises questions about whether the results are generalisable. Some patients were excluded to prevent inclusion of diarrhoea from other causes and some patients were excluded because of a lack of informed consent; these factors are irrelevant in routine use and amounted to 79% of exclusions in this trial. Others were excluded to ensure safety, and 21% were excluded on these grounds. Infections such as endocarditis or bacteraemia are rare, and recent safety reviews have questioned whether probiotics were actually the cause of infection in some documented cases.

Nevertheless, we were cautious when recruiting for this study. Such strict criteria, however, may not be needed in practice. The high refusal rate (148) is unsurprising as we were approaching mainly elderly patients early in their hospital stay. The need for extensive data collection, monitoring, and collection of stool samples will certainly have discouraged some patients. Should probiotics become routinely used in hospitals patients will certainly have discouraged some patients. Account safety concerns for specific patients.

Table 3 | Risk model for prediction of antibiotic associated diarrhoea with logistic regression

<table>
<thead>
<tr>
<th></th>
<th>Odds ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment (probiotic=1, placebo=0)</td>
<td>0.25 (0.07 to 0.85)</td>
</tr>
<tr>
<td>Plasma sodium</td>
<td>0.84 (0.75 to 0.95)</td>
</tr>
<tr>
<td>Serum albumin</td>
<td>0.82 (0.73 to 0.92)</td>
</tr>
</tbody>
</table>

Additional information is available on bmj.com.

DISCUSSION

Twice daily intake of a probiotic drink containing L casei, L bulgaricus, and S thermophilus for one week longer than the duration of antibiotic treatment can prevent diarrhoea associated with antibiotic use and that caused by C difficile. There were no adverse events and the drink was well accepted. This is a major advance on previous meta-analyses, which called for further definitive trials and expressed considerable doubt as to the efficacy in preventing C difficile associated diarrhoea.

Strengths and weaknesses

This study was adequately powered for the large treatment effect in antibiotic associated diarrhoea and used a probiotic freely available in the UK. Additionally, we couldn’t establish which bacteria species are effective from the three strains in this probiotic drink; the three species may be working synergistically to prevent diarrhoea or alternatively one species may be more effective than another. Therefore, our results cannot be extrapolated to other probiotic products, which must be tested in similar trials.

The obvious methodological weakness is the possibility of unblinding of the researchers and patients. We did, however, take precautions to avoid unblinding and, most importantly, several people confirmed the presence of diarrhoea. The loss to follow-up of 16% of the study population is also a weakness, though the numbers lost in each group were similar (12 in the probiotic group and 10 in the control group) and should not significantly alter the results.

The figure illustrates the difficulties in recruitment for this study; of 1760 patients screened only 135 took part. This raises questions about whether the results are generalisable. Some patients were excluded to prevent inclusion of diarrhoea from other causes and some patients were excluded because of a lack of informed consent; these factors are irrelevant in routine use and amounted to 79% of exclusions in this trial. Others were excluded to ensure safety, and 21% were excluded on these grounds. Infections such as endocarditis or bacteraemia are rare, and recent safety reviews have questioned whether probiotics were actually the cause of infection in some documented cases.

Nevertheless, we were cautious when recruiting for this study. Such strict criteria, however, may not be needed in practice. The high refusal rate (148) is unsurprising as we were approaching mainly elderly patients early in their hospital stay. The need for extensive data collection, monitoring, and collection of stool samples will certainly have discouraged some patients. Should probiotics become routinely used in hospitals patients are far more likely to accept it as an established rather than a trial treatment. Thus, we think the results can be generalised to any older patients in hospital, taking into account safety concerns for specific patients.

Costs

Using the numbers needed to treat (5 for antibiotic associated diarrhoea, 6 for C difficile associated diarrhoea) we calculated the cost to prevent one case of antibiotic associated diarrhoea. The estimated average cost of the probiotic was £10 (€14.8; $20) per patient (assuming an average antibiotic course of 10 days plus a further seven days of probiotics, and using current retail prices for Actimel, about £0.30 (€0.44; $0.60) each). The cost to prevent one case would therefore be £50 (€74; $100) for antibiotic associated diarrhoea...
WHAT IS ALREADY KNOWN ON THIS TOPIC
Probiotics may prevent diarrhoea associated with antibiotics and *Clostridium difficile*. Adequately powered, double blind randomised controlled trials are needed to assess the efficacy of specific probiotic strains. Evidence for the efficacy of probiotic products readily available in the UK is lacking.

WHAT THIS STUDY ADDS
Consumption of a readily available probiotic drink containing *Lactobacillus casei*, *L. bulgaricus*, and *Streptococcus thermophilus*, twice a day during a course of antibiotics and for one week afterwards, reduces the incidence of diarrhoea associated with antibiotic use and *C. difficile*. Compliance with the probiotic drink was good.

The cost to prevent one case of diarrhoea was £50 (£74; $100) and £60 (£87.5; $120) to prevent one case of *C. difficile*.

and £60 (£89; $120) for *C. difficile* associated diarrhoea, excluding dispensing and nursing costs. Evidence suggests that additional treatment costs per patient for *C. difficile* associated diarrhoea are on average £3669 (£1835; £2738) in the United States\(^1\) and £4000 (£5920; £8000) in the United Kingdom\(^2\), mainly because of increased length of stay in hospital but also because of the use of vancomycin. Clearly substantial savings could be made by the routine use of probiotics.

We thank Winston Banya for statistical advice and conducting the randomisation. Sheila Bacon, Paula Brown, and Linda Wedlake for assistance with data collection. Edward Pawley, Lucy O’Driscoll, Regina Storch, Kuldip Dehal, and the pharmacy departments at each hospital for management and dispensing of the study drinks, the nursing staff on all the wards involved for help with keeping stool charts, monitoring patients, and collecting stool samples; Manfred Almeida and the staff in the division of microbiology, Hammersmith Hospitals Trust, for help with lactobacilli counts and *C. difficile* toxin tests, and Ruth Peters for organising data entry.

**Contributors:** ALD’s, MH, CJB, CR, SW, and TRR were all involved in the preparation of the protocol, ALD’s, CJB, and MH obtained ethical approval; ALD’s, CJB, CR, and TRR obtained funding; MH, NM, and ALD’s recruited patients and collected data; MH managed the running of the trial; TRR set up and SW undertook the microbiological investigations; MH and ALD’s undertook data cleaning and analysis with the assistance of CR and CJB, all authors assisted in the production of the manuscript and interpretation of the results and all approved the final version. MH is guarantor.

**Funding:** Healthcare Foundation and Hammersmith Hospital Trustees research committee and Danone Vitapole (Paris, France). The Healthcare Foundation made initial comments on the design of the study. Once funding was agreed none of the funding sources had any role in the data collection, analysis, interpretation of data, writing of the report, or the decision to submit the paper for publication.

**Competing interests:** CB, MH, and ALD’s have received funding from Danone to attend Danone International Conferences on Probiotics. CJB is a member of Danone UK advisory group.

**Ethical approval:** London multicentre research ethics committee.


Accepted: 11 May 2007